# US 2015/0175713 A1 · Lh-type bispecific antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175713 A1
- Document ID: US20150175713A1
- Status: Published application
- Kind: A1
- Application number: 14/597,969
- Filed: 2015-01-15
- Published: 2015-06-25
- Earliest claimed: 2009-03-25
- Assignees: Tohoku University
- Applicants: Tohoku University
- Inventors: Izumi KUMAGAI; Ryutaro ASANO; Mitsuo UMETSU
- Web page: https://patentgrep.com/patent/US20150175713A1

## CPC

- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.

## Claims

### Claim 1

A nucleic acid molecule encoding the single-chain polypeptide constituting the diabody-type bispecific antibody consisting of a first polypeptide comprising a humanized variable region of the light chain (5L) of an anti-human EGF receptor 1 antibody 528 and a humanized variable region of the heavy chain (OH) of an anti-CD3 antibody OKT in this order from its N-end to C-end; and a second polypeptide comprising a humanized variable region of the light chain (OL) of an anti-CD3 antibody OKT and a humanized variable region of the heavy chain (5H) of an anti-human EGF receptor 1 antibody 528 in this order from its N-end to C-end.

### Claim 2 (depends on 1)

A nucleic acid molecule encoding both of the two kinds of the single-chain polypeptides constituting the bispecific antibody of claim 1.

### Claim 3 (depends on 1)

A replicable cloning vector or an expression vector containing the nucleic acid molecule of claim 1.

### Claim 4 (depends on 3)

The vector of claim 3, which is a co-expression vector.

### Claim 5 (depends on 3)

The vector of claim 3, which is a plasmid vector.

### Claim 6 (depends on 3)

A host cell transformed with the vector of claim 3.

### Claim 7 (depends on 6)

The host cell of claim 6, which is a prokaryotic cell.

### Claim 8 (depends on 7)

The host cell of claim 7, which is E. coli.

### Claim 9 (depends on 6)

A method for the production of the bispecific antibody, comprising culturing a host cell according to claim 6 to express the two kinds of the single-chain polypeptides constituting said bispecific antibody, collecting and purifying said single-chain polypeptides, assembling the two kinds of the single-chain polypeptides, and separating and collecting the bispecific antibody thus formed.

### Claim 10 (depends on 9)

The method of claim 9 wherein the host cell is E. coli, and the two kinds of the single-chain polypeptides are collected from supernatant of a culture medium, periplasm fraction, intracellular soluble fraction or intracellular insoluble fraction.

### Claim 11 (depends on 4)

A method for the production of the bispecific antibody, comprising culturing a host cell transformed with the co-expression vector of claim 4 to express the two kinds of the single-chain polypeptides constituting said bispecific antibody, allowing the transformed cell to form the diabody-type bispecific antibody in said cell, and separating and collecting the bispecific antibody thus formed.

### Claim 12

A method for the production of a humanized diabody-type bispecific antibody consisting of two kinds of the single-chain polypeptides of (5L OH) and (OL5H) or a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having the structure:
(5LOH)-(a peptide linker)-(OL5H) or (OL5H)-(a peptide linker)-(5LOH),
the method comprising:
digesting with a protease to cleave the Fc region and the hinge region a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having the structure of an antibody wherein a humanized diabody-type bispecific antibody consisting of two kinds of the single-chain polypeptides of (5LOH) and (OL5H) is bonded to two Fc regions of a human antibody via each hinge region through either of the two single-chain polypeptides wherein the humanized diabody-type bispecific antibody is bonded to the hinge regions via a protease cleavage site.

### Claim 13

A method for the production of a humanized diabody-type bispecific antibody consisting of two kinds of the single-chain polypeptides of (5L OH) and (OL5H) or a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having the structure:
(5LOH)-(a peptide linker)-(OL5H) or (OL5H)-(a peptide linker)-(5LOH),
the method comprising:
digesting with a protease to cleave the Fc region and the hinge region a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having the structure of an antibody wherein the single-chain polypeptide of (5LOH)-(a peptide linker)-(OL5H) or (OL5H)-(a peptide linker)-(5LOH) is bonded to two Fc regions of a human antibody via each hinge region wherein the single-chain polypeptide is bonded to the hinge regions via a protease cleavage site.
